CLINICAL_TRIALS ClinicalTrials.gov record with results posted

A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03603808
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-29T15:20:05.597507+00:00
Published At: 2026-04-29T00:00:00+00:00
Record Updated At: 2026-04-29
Results Posted At: 2026-04-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Anal Intraepithelial Neoplasia", "High Grade Squamous Intraepithelial Neoplasia", "HIV Positivity", "Human Papillomavirus-16 Positive", "Human Papillomavirus-18 Positive"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-29"
protocolSection.identificationModule.nctId: "NCT03603808"
protocolSection.identificationModule.officialTitle: "A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-04-29"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.